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Background: Obesity is of major pathogenetic importance to type 2 diabetes, it contributes to poor glycemic
control and increases the risk of cardiovascular disease. Over 80% of patients with diabetes type 2 are overweight.
To achieve a more favourable risk profile, changes in diet and lifestyle are needed. However, current treatment
programs for obese DM type 2 patients are not effective in the long term. In this RCT, we compare the
effectiveness of a Combined Psychological Intervention (CPI) and usual care in maintaining the favourable effects
on weight and risk profile during 2 years of follow-up after a Very Low Calorie Diet (VLCD).
Methods and design: In a randomised parallel group intervention study, 140 patients with type 2 diabetes and
overweight (BMI>27 kg/m2) will be recruited from the outpatient department of the Erasmus Medical Centre.
After obtaining ≥5% of weight loss with a VLCD, participants will be randomly assigned to CPI or usual care for 10
weeks. CPI consists of cognitive behaviour therapy, problem solving therapy and proactive coping.
Primary outcome measure is weight change (kg).
Other outcome measures are Body Mass Index (BMI = weight (kg)/length (m)2), waist circumference (cm), systolic
blood pressure (mmHg), HbA1c (mmol/mol), lipid levels (LDL, HDL, TG (mmol/l) and chol/HDL-ratio), antidiabetic
agents and doses, cardiovascular risk profile (UKPDS), lifestyle and quality of life (EuroQol EQ-5D). Psychosocial
parameters are also studied, as secondary outcomes as well as determinants for weight loss.
When successful, we want to conduct an analysis of the cost effectiveness of the intervention as compared to
usual care.
Discussion: We expect that a CPI after a VLCD will be effective in maintaining weight loss and improving
cardiovascular risk and glycaemic control, while being cost-effective and improving quality of life in patients with
type 2 diabetes.
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Diabetes has become a worldwide epidemic: the esti-
mated global prevalence was 2,8% in 2000 and is
expected to rise up to 4,4% in 2030. In the year 2000 the
excess global mortality attributable to diabetes was 5,2%
making diabetes the fifth leading cause of death [1]. The
increase in prevalence is associated with aging of the
population, the increasing prevalence of obesity in com-
bination with physical inactivity. Cardiovascular disease
is the major cause of death among patients with dia-
betes. An intensive pharmaceutical and behavioral ther-
apy treatment has been estimated to reduce the risk of
cardiovascular and micro vascular events by approxi-
mately 50% [2].
Approximately 80% of the people with type 2 diabetes
are overweight. Losing weight is the cornerstone of pre-
vention and treatment of type 2 diabetes: it decreases
the resistance to insulin, improves glycaemic control and
reduces hypertension and lipid abnormalities [3-5].
Weight loss interventions thus may contribute to a re-
duction of cardiovascular risk and is shown to reduce
mortality in patients with type 2 diabetes and obesity [6].
Unfortunately, interventions aimed at weight reduc-
tion have only a limited effect in the long run because of
regain of the initial weight loss. The required long-term
lifestyle change seems difficult to achieve [7]. A meta-
analysis of weight loss interventions in adults with type
2 diabetes showed that multi-component interventions
including Very Low Calorie Diets may hold promise for
achieving weight loss [7,8]. However, trials with long
follow-up periods are lacking and the most effective type
of psychological intervention remains unclear.
In the present study, we determine the effect of an
integrated multi-model cognitive group therapy, in
obtaining and maintaining favourable effects on weight
and cardiovascular risk profile during 2 years of follow-
up after a Very Low Calorie Diet.
Very Low calorie diet
A Very Low Calorie Diet (VLCD) is a diet of less than
800 kilocalories (kcal) daily [4]. The very low intake of
fat and carbohydrates, but normal amount of proteins
(0,8 g/kg ideal bodyweight per day) enhances lipolysis
and ketosis while preventing a negative nitrogen balance,
sparing lean body mass [9].
The most commonly used VLCD’s are commercially
available mixed-formula diets, containing various
amounts of carbohydrate, fat and high quality protein,
and have proven safety for use in patients with type 2
diabetes [9,10].
The short-term effects (i.e. < 6 months) of a VLCD in
overweight patients with type 2 diabetes are favourable
on weight, glycaemic control, hypertension and dyslipi-
daemia [11-15]. However, study outcomes are lesspositive in the long term (i.e. > 1 year follow-up):
patients regain most of the lost weight and HbA1c
returns to the same value as prior to the intervention.
Nonetheless, participants often needed less anti-diabetic
agents [16-18]. The study of Jazet, et al. [19] seems to be
a positive exception: 18 months after a 30-day VLCD
period, favourable effects on weight, blood pressure and
dyslipidaemia were maintained in 18 obese patients with
diabetes type 2, but with no effect on HbA1c. The
authors indicated that the success was based on the
strong motivation of the patients to prevent a need for
insulin and a slow reintroduction of normal diet. Limita-
tions of this study, however, were the small intervention
group and the lack of a control group.
Taken together, randomized controlled trials of suffi-
cient duration focused on prevention of weight gain after
a VLCD in DM type 2 patients are required to improve
the effectiveness of VLCDs.
Weight maintenance
To achieve weight maintenance after successful weight
loss, a permanent behaviour change is needed. For this
purpose, a variety of psychological interventions have
been implemented in weight reduction programmes. Be-
haviour therapy and cognitive behaviour therapy (CBT)
are potential psychological interventions facilitating bet-
ter maintenance of weight loss [20]. CBT is used to de-
scribe a wide range of techniques to change thinking
patterns and behaviours. As a result, interventions are
heterogeneous and the findings are difficult to compare.
We identified three promising psychological interven-
tions to attain better results in sustaining weight loss:
cognitive (behaviour) therapy, problem solving therapy
and proactive coping. In the current study, we propose
to combine them into an integrated weight maintenance
programme.
Cognitive behaviour therapy
Within cognitive psychology, humans are regarded as in-
formation processing systems, where knowledge is orga-
nized in so-called schemas. Cognitive schemas are
activated by incoming information, leading to cognitions
(thoughts), emotions and subsequently to behaviour.
According to the founding father of the cognitive ther-
apy, Aaron Beck, emotional disorders such as depression
and anxiety disorders result from dysfunctional schemas.
Cognitive therapy focuses on changing dysfunctional
schemas and cognitions, using behavioral experiments
and challenges [21]. In eating disorders, the cognitive
model was first used to treat bulimia nervosa by adjust-
ing overvaluation of weight and shape based on low self-
esteem [22,23]. In the treatment of obesity, this model is
combined with the cognitive model for addiction, which
is based on the assumption that addictive behaviour is
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to external stimuli like the smell or sight of food [24].
In a Cochrane review [20] concerning the effect of
psychological interventions in the treatment of over-
weight and obese patients, positive effects of cognitive
behaviour treatment on weight loss were described, par-
ticularly when combined with diet and/or physical activ-
ity. In a number of studies, weight loss was enhanced
significantly by the addition of the cognitive component
to an intervention of diet and/or exercise [25-28]. More-
over, it was found that a longer duration of the interven-
tion and more frequent clinical contact was associated
with an increased effect. However, studies with substan-
tial follow-up (i.e. > 1 year) are lacking.
In patients with type 2 diabetes, psychotherapy (espe-
cially CBT) improves glycaemic control (HbA1c −1,0%)
and psychological well-being [29]. Surprisingly, CBT did
not appear to affect weight control in this patient group.
Perhaps this was caused by too short duration of the
studies (i.e. <6 months), as CBT may encourage long-
term behavioral changes [29].
Problem solving therapy
Problem Solving Therapy (PST) is defined as the self-
directed cognitive-behavioral process by which a person
attempts to identify effective or adaptive solutions for
specific problems encountered in everyday living [30,31].
PST is recognized as an effective treatment of depression
[32,33]. The problem-solving model for obesity treat-
ment was first described by Perri, Nezu and Viegener in
1992 [34] and proposes that active problem solving
efforts by a health care provider can help the obese per-
son encounter everyday problems in their weight man-
agement. Perri, et al. found significantly greater long-
term weight reductions in participants, who completed a
PST-intervention, compared to participants receiving be-
havioral therapy [35]. Moreover, a recent study showed
that people with better problem-solving skills lost more
weight and were more compliant to therapy [36].Proactive coping
Proactive coping (PC), directed at an upcoming instead
of an ongoing stressor, is a new focus in positive psych-
ology research. PC consists of efforts undertaken in ad-
vance of a potentially stressful event to prevent it or
modify its form before it occurs. The theory described
by Aspinwall and Taylor consists of five stages: PC starts
with the ‘accumulation of resources’ such as time,
money, planning or organizational skills and social sup-
port, so that one is prepared as much as possible to deal
with future threats. ‘Recognition’ refers to the ability to
see a potential stressful event coming, followed by ‘initial
appraisal’ (what is this and should I be worried aboutthis?). The next stage consists of ‘initial coping efforts’:
activities undertaken to prevent or minimize a recog-
nized or suspected stressor. Finally, the ‘use of feedback’
involves the evaluation of the stressful event itself and
the effects of one’s preliminary efforts [37].
Schwarzer and Taubert described PC as a way of aspir-
ing a positive future by accumulating resources and real-
istic goal setting [38]. A recent publication has shown
that the pursuit of goals was related to improved well-
being, while preventing a negative future was not [39].
A study of the effects of PC on the self-care beha-
viours of newly diagnosed DM patients revealed that the
treatment was highly appreciated and even after 9
months improvements in eating and exercising habits
were seen. In addition, the intervention was effective in
reducing both weight and blood pressure after 9 months,
but had no effect on HbA1c or lipid profile [40].
In the current randomized study, we compare the ef-
fect of a Combined Psychological Intervention (CPI)
with usual care on weight maintenance after a Very Low
Calorie Diet. Hence, we do not compare the effective-
ness of Cognitive Behaviour Therapy with neither Prob-
lem Solving Therapy nor Proactive Coping, but combine
these three therapies into an integrated multi-model
program.
Objectives
The primary objective of this study is to determine if an
integrated multi-model cognitive group therapy, is more
effective in preventing weight regain after a Very Low
Calorie Diet compared to usual care.
The secondary objectives are to investigate whether an
integrated multi-model cognitive group therapy follow-
ing a VLCD has an effect on glycaemic control, cardio-
vascular risk profile, psychological variables and quality
of life, and subsequently to determine which patient
group benefits most of the intervention.
The tertiary objective is to determine whether the
intervention is cost-effective.
Ethical approval
This research is approved by the Medical Ethics Com-
mittee of the Erasmus Medical Centre in Rotterdam
(reference number MEC-2009-143/NL26508.078.09), in
compliance with the Helsinki Declaration.
Methods/design
Design of the study
This study is a randomized controlled parallel group
intervention trial.
When patients lose equally or more than 5% of their
bodyweight in the first 8 weeks of the VLCD, they are
included in the intervention trial testing CPI. This arbi-
trary cut-off value was chosen because of its relatively
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relevant weight loss to investigate weight maintenance
after weight reduction. After randomization, stratified to
the achieved weight loss at 8 weeks, participants are
assigned to one of the following conditions:
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by two 2-weekly sessions, two monthly sessions, two 3-
monthly sessions and 1 session with an interval of
6 months.
Outcome measurements are assessed at baseline, after
finishing the intensive CPI-period at 4 months and sub-
sequently at 1 year, 1,5 years and 2 years after
randomization. At 8 weeks (randomization after VLCD),
only the primary outcome (weight) will be measured.
Figure 1 shows the design of the study.
The study started in may 2010 with a pilot and inclu-
sion will be completed in 2013. The follow-up will con-
tinue until 2015.
Study population
Patients are recruited from the outpatient diabetes clinic
of the Erasmus Medical Centre in Rotterdam by the
medical team, based on the in- and exclusion criteria
shown in Table 1. In our hospital, a tertiary referral
centre, we see both patients with only oral antidiabetic
agents and patients treated with one or more insulin
doses daily. In general, our patients will have more com-
plex disease and more comorbidity compared to the
average diabetic patient referred to a GP. How ever, GP’s
can also directly refer their eligible patients to our trial.
Patients interested in participating in the study will re-
ceive an information letter and a questionnaire to be
filled in at home. Two weeks later they will visit the out-
patient clinic for an intake interview with the researcher
(KACB). Eligibility will be checked again. After signing
the informed consent form by the patient, the baseline
measurements will be performed.
Patients with psychiatric disorders or major psycho-
logical disturbances are excluded from the trial. Patients
with eating disorders (bulimia nervosa and binge eating
disorder) or depression are not excluded, since it isTable 1 Eligibility
Inclusion criteria:
1 Diagnosed diabetes mellitus type 2
2 Age 18–75 years
3 BMI ≥ 27 kg/m2
Exclusion criteria:
6 Pregnancy or lactation during the study
7 Inadequate expression of the Dutch language (spoken and written)
8 Inability to lose ≥ 5% of bodyweight during the first 8 weeks of
VLCD
9 Severe psychiatric problems
10 Significant cardiac arrhythmias, unstable angina, decompensated
congestive heart failure, major organ system failure, untreated
hypothyroidism and/or myocardial infarction, end-stage renal
disease, cerebrovascular accident or major surgery in the last 3
months.expected that these conditions are common among
patients with type 2 diabetes and previous research has
shown that cognitive behaviour therapy can have benefi-
cial effects in these patient groups [28,41-43]. We will
analyze the effect of these background variables on the
outcome of the intervention.
Randomization
Groups of 20 patients will start with a VLCD concomi-
tantly. After 8 weeks of VLCD, the patients who lost
≥5% of bodyweight are randomly assigned to either or
the intervention group (usual care + CPI) or the control
group (usual care) with an allocation ratio of 1:1. The
stratified randomization is computer controlled, carried
out by a secretary and supervised by a statistician, who
are both not involved in the trial. The reason for a strati-
fied randomization is to avoid an unsuccessful
randomization with regard to weight loss during the
VLCD. It is not possible to correct afterwards in the
analysis, as it is the primary outcome measurement. We
defined the following strata (based on clinical
experience):
1. 5% - 7,5%
2. 7,5% - 10%
3. >10% weight loss after 8 weeks of VLCD.
The statistician generates the allocation sequence and
hands it over to the secretary of the department of Med-
ical Psychology and Psychotherapy, who is not involved
in the study, to guarantee allocation concealment. The
secretary assigns the participants to their group and
makes a list for KACB, who will plan their study
appointments.
Sample size calculation
After randomization of 75 participants, the sample size
calculation was carried out by an independent statisti-
cian to base it on realistic data.
Sample size was calculated with SPSS 17.0, using
the mixed-model ANOVA procedure described by
Aberson [44].
Alpha was set at 0.05, power at 0.80 and the baseline-
end correlation at 0.90. A clinically relevant difference
between the treatment groups is 5% weight loss [3].
Mean weight at the start of the treatment is about
110 kg, with a standard deviation of 22, this equals an
effect size of d = 0.25.[45] With this power calculation
we estimate that we need 52 patients in each group.
Anticipating a dropout rate of 25%, we aim for a total
sample size of 140.
For the most important secondary outcomes we calcu-
lated the detectable difference with the sample size of
n=104, alpha 0.05 and power 0.80 (Table 2). The
Table 2 Power calculation secondary outcomes
Secondary outcome: SD: Detectable difference:(n = 104, β=0.8 α=0.05)
Waist circumference 11 2.75 cm
Blood pressure sys/dias 20/20 5/5 mmHg
Total cholesterol 1.4 0.35 mmol/l
LDL cholesterol 1.0 0.25 mmol/l
HDL cholesterol 0.7 0.2 mmol/l
Triglyceride 3.0 0.75 mmol/l
HbA1c 12 3 mmol/mol
Insulin 50 12.5 IU
Depression (HADS score 0–21) 3 0.75
Anxiety (HADS score 0–21) 4 1.0
Self esteem (RSE score 10–40) 5 1.25
Fatigue (CIS score 8–56) 13 3.25
Concentration (CIS score 5–35) 8.5 2.1
Motivation (CIS score 4–28) 6 1.5
Activity (CIS score 3–21) 5 1.25
Quality of life (EuroQol 5D score 1–3) 0.5 0.125
Quality of life (EuroQol VAS 1–100) 21 5.25
Berk et al. BMC Public Health 2012, 12:1026 Page 6 of 14
http://www.biomedcentral.com/1471-2458/12/1026detectable differences are quite small, so the aimed sam-
ple size seems adequate to analyse at least these second-
ary outcomes.
Blinding
Given the nature of the intervention, it is impossible to
blind the participants, CPI-therapist and researcher
(KACB). Nevertheless, we will try to keep the interven-
tion as separate as possible from the diabetes treatment,
by giving participants strict instructions not to commu-
nicate about the intervention with their medical team.
Patients are given the possibility to discuss problems
related to the study with an independent medical doctor.
The CPI group sessions will take place in another part
of the hospital, outside the diabetes clinic, to ensure that
patients and medical team will not run into each other.
The VLCD is not a part of the intervention and can
therefore be guided by the diabetes medical team.
To avoid bias, measurements will be conducted by
blinded medical assistants and analyses will be done by
two analysts, independent of each other.
The allocation sequence will be revealed to the
researchers once recruitment, data collection and ana-
lyses are complete.Interventions
Phase 0: very Low calorie diet
The first part of the study (before randomization) is the
same for all participants and consists of a Very Low Cal-
orie Diet (VLCD) for the duration of 8 weeks, with aphase-out of 12 weeks. When after 8 weeks of VLCD a
loss of 5% or more of the initial bodyweight is reached,
random allocation to the intervention- and control
group will take place. Patients losing less then 5% of
bodyweight in the first 8 weeks are excluded from the
study and will receive usual care, including dietary
advice.
The use of a VLCD is an integrated part of the dietary
treatment at our outpatient diabetes clinic. Normally,
the patients are free to choose between the different
types of weight reduction strategies. In the present study
however, only one type of weight reduction therapy is
used (VLCD).
The product we use for this study is Glucerna SRW, a
product specifically developed for patients with diabetes
and based on a combination of slow released carbohy-
drates, a low-fat, high monounsaturated fatty acid con-
tent and the addition of dietary fibre. Various studies
indicate that this product decreases the postprandial
blood glucose levels, which may have a lowering effect
on HbA1c. This diabetes-specific diet product is also
used as a meal replacement for achieving weight reduc-
tion in people with type 2 diabetes, with positive effects
on weight control, glycaemic control and lipid profile
[46-48]. We have chosen to use a twice a day regimen of
meal replacements, together with a small dinner, provid-
ing 750 kcal, 67 g carbohydrates, 54 g protein and 32 g
fat (of which 16 g monounsaturated fatty acids (MUFA))
a day and RDA recommendations in micronutrients. We
believe that enabling the participants to have dinner with
their family during the VLCD will improve compliance.
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in patients with type 2 diabetes, where we describe the
different aspects of the treatment. Oral anti-diabetic
agents (except Metformin) and short-acting insulin ana-
logues are discontinued, while the dosage of long-acting
insulin analogues and biphasic mixtures is halved, to
avoid severe hypoglycaemia. GLP-1 or DPP-4 inhibitors
will be continued. During the VLCD and gradual transi-
tion to a normal diet, medication is adjusted by means
of glucose self-control and frequent contact with dia-
betes nurses and dieticians. The dose of any antihyper-
tensive medication is also adjusted during VLCD and
follow-up, in consultation with the responsible
physician.
Realimentation takes place by slowly reintroducing
normal food in 12 weeks time, until participants use a
lightly energy restricted diet (1300 kcal a day), according
to national dietary guidelines.Phase 1: control group
Following the VLCD-period and gradual reintroduction
of normal diet, the control group receives usual care,
provided by the diabetes team of the out-patient diabetes
clinic of the Erasmus Medical Centre. Usual care con-
sists of a 3-monthly visit to the physician and diabetes
nurse, including medical examinations. Dietary treat-
ment is part of usual care by referral to a specialized
dietician. Patients are free to make additional appoint-
ments with their dietician in- or outside the hospital and
they can choose to follow whatever diet they would like
during the follow-up period. Both the number of visits
to a dietician and the dieting methods, products and
duration of the diet are noted during the follow-up
period of 2 years. Dieticians in our hospital are all
trained in motivational interviewing to motivate the
patients in changing their lifestyle. All members of the
diabetic team encourage the patients to get enough exer-
cise, but we do not refer to an exercise programme.
Patients in need of psychological help (ie psychological
disorder, clinical depression, major eating disorder)
are referred to a clinical psychologist in- or outside the
hospital. In our population, these referrals are rare.
Nonetheless, the number of visits to a psychologist
as well as to other caregivers will be noted during this
trial. CBT or techniques of PST and PC are no part of
usual care.
Phase 1: intervention group
After 8 weeks of VLCD, the participants allocated to the
intervention group start with CPI in groups of up to 10
patients, in addition to the basic treatment for diabetes
and obesity, focusing on (self ) regulation of blood glu-
cose and the prevention/reduction of complications,according to national guidelines. The CPI sessions are
guided by a trained psychologist/psychotherapist, with
experience in diabetes care. Two psychologists (HB and
AVTS) are involved in this study, so we can investigate
the ‘therapist-effect’.
The first 10 weekly sessions consist of cognitive behav-
iour therapy, partly based on the method developed by
Werrij and colleagues from the University of Maastricht
[27]. These CBT meetings are followed by 7 relapse pre-
vention sessions.
The aim of the first 10 sessions is to restructure dys-
functional cognitions on lifestyle, weight and body
perception.
Sessions 11–17 aim to prevent relapse by combining
intervention techniques of CBT, PC and PST. Table 3
presents the treatment protocol in brief.
After session 1, the structure of each session is as
follows:
– time for questions following the previous session
– discussing home-assignments
– explaining and practicing of cognitive (behavioral)
techniques
– discussing new home-assignments
– summary and evaluation of the session (by
completing the Session Rating Scale)
In sessions 1–5 dysfunctional cognitions about eating,
weight and shape are identified and challenged. Also ex-
ercise will be included in the sessions. Cognitive diaries
are introduced and participants are encouraged to use
these diaries at home to record personal critical situa-
tions and dysfunctional thoughts. They also score the
credibility of their dysfunctional thoughts (0-100%). Fur-
thermore, the validity of the dysfunctional thoughts is
tested and alternative thoughts are generated. Guided by
examples of the group, the group is acting as a research
team, investigating the validity of dysfunctional cogni-
tions and creating alternative and more realistic
thoughts. The new thoughts are again scored on cred-
ibility (0-100%). Methods used for testing the validity of
a person’s thoughts are the Socratic dialogue and behav-
ioral experiments. Behavioral experiments are set up
during the session, carried out at home, and discussed in
the next session.
The underlying schemas (‘core beliefs’) are explored
during sessions 6–10. The validity of self schemas is
tested in the same way as the other dysfunctional
thoughts and recorded in the diary.
Subsequently, 7 relapse prevention meetings are held
to stabilize behaviour change, with increasing intervals
until the end of the study (2 years). During these relapse
prevention meetings, the acquired techniques will be
repeated. In addition, techniques of Problem Solving
Table 3 Brief presentation of the treatment protocol
Weekly sessions
Session 1 Introduction of the therapist and the group members
Agreements on attendance, commitment, homework and privacy
Setting realistic treatment goals
Explaining the rationale of the cognitive treatment
Introducing relevant concepts op CBT (situation, thoughts, emotions, behavior) and the use of the diary
Sessions 2 – 4 Discussing rationale and the concepts of CBT
Explaining unrealistic and automatic thoughts
Identifying and challenging dysfunctional cognitions about eating, weight and shape (by Socratic dialogue)
Homework: cognitive diaries
Sessions 5 – 8 Introducing the behavioral experiment
Challenging dysfunctional cognitions by setting up a behavioral experiment
Identifying and challenging ‘core beliefs’, the underlying self-schemas
Homework: cognitive diaries and behavioral experiments
Sessions 9 – 10 Preparing for the oncoming ending of weekly sessions
Identifying and challenging dysfunctional cognitions about relapse
Introducing relapse prevention sessions
Relapse prevention sessions
Session 11 Challenging dysfunctional cognitions about relapse
Setting goals for the long term
Explaining Problem Solving Treatment and Proactive Coping
Session 12 – 16 Implementing PST and PC in an individual plan
Session 17 Preparing for treatment ending
Challenging dysfunctional cognitions about treatment ending
Personal reminder in difficult times
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day problems they encounter while implementing their
lifestyle changes. Based on individually set goals, experi-
enced problems are identified and possible solutions will
be put forward in a group brainstorm session. The par-
ticipant will choose the most appropriate solution and
creates and carries out an implementation plan. In this
plan, the participant formulates the solution as a
SMART (Specific, Measurable, Attainable, Realistic,
Timely) goal and considers which steps should be taken
to achieve this goal. Subsequently, the participants will
be encouraged to identify barriers that may arise while
trying to achieve their goals. Under guidance of the
psychologist, activities will be defined which can be
undertaken to prevent the occurrence or diminish the
effect of these potentially threats (Proactive Coping).In
following relapse prevention sessions, the implementa-
tion plan is evaluated and new (sub) problems are
chosen to tackle. By linking Problem Solving Therapy to
Proactive Coping and cognitive restructuring of (relapse)
thoughts, we hope to have created a powerful interven-
tion to provide participants skills to prevent and cope
with relapse in their behaviour.Outcome assessment
Outcome measurements (see below) are assessed at
baseline (before start VLCD), and again at 4 months
(after VLCD and 10 CPI sessions), 1 year, 1 ½ years and
2 years.
Demographic variables are assessed at baseline by use
of a self-administered questionnaire, which is checked
during the intake interview with the investigator.
All other secondary outcomes are assessed at baseline,
after 4 months, 1 year, 1 ½ years and 2 years, using self-
administered questionnaires, except of the Session Rat-
ing Scale, which is filled in after every CPI session.
Data are managed by use of the trial management sys-
tem ‘EXPeRT Clinical’ of OmniComm, USA.Primary outcome
The primary endpoint with respect to the efficacy of CPI
is the differential course of weight (kg) between both
study groups, measured at 8 weeks and at 2 years fol-
low-up. Weight is measured to the nearest 0.1 kg, after
removal of shoes using a Seca 888 compact digital flat
scale.
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1. Anthropometric measurements: Height is measured
to the nearest 0.5 cm without shoes using a Seca
stadiometer. Body Mass Index is calculated as weight
divided by height squared (BMI = weight (kg)/height
(m)2). Waist circumference (cm) is measured at the
level midway between the lowest rib margin and the
aliac crest. Hip circumference is measured at the
widest point over the buttocks. Both waist- and hip
circumference are measured by the nearest 0,5 cm,
using a tape-measure. Subsequently, waist-hip ratio
(WHR) is calculated.
2. Cardiovascular riskprofile by use of the UKPDS risk
engine [49]:a. Systolic and diastolic blood pressure (mmHg) are
measured twice in upright position, while the
patient had rested for at least 5 minutes with an
Omron M4-I Intelli-sense device. The second
value will be used.
b. Blood samples are taken to asses total cholesterol,
LDL-cholesterol, HDL-cholesterol and triglycerides
(mmol/l), measured on a Roche Modular P 800,
reagents used from Roche, methods used from
Roche are Cholesterol Chod-pap, HDL-c plus 3rd
generation, LDL-c plus 2nd generation and
Triglycerides GPO-PAP.
3. Glycaemic control:
a. HbA1c (mmol/mol), measured on a Menarini HA-
8160, reversed-phase action exchange
chromatography.
b.HOMA-%S calculated by measuring fasting plasma
glucose (mmol/l), (measured on a Roche Modular
P 800, reagent used from Roche, method used
from Roche is Glucose Hexokinase) and fasting
insulin (mmol/l)
c. Glucose lowering medication (insulin (IU/day) and
antidiabetic agents (mg/day))
4. Psychological measurements
a. Anxiety and depression are measured by the
Hospital Anxiety and Depression Scale (HADS)
[50,51]. The HADS consists of a 7-item
Anxiety scale and a 7-item Depression Scale.
The items are scored from 0 to 3 and the
range of scores is 0 – 21. A score between 0
and 7 excludes depression/anxiety. A score of
8–10 indicates a possible depression/anxiety. A
score of 11–21 is indicative of a probable
depression/anxiety.b. Somatic symptoms are measured by the VOEG-13
(‘Vragenlijst Onderzoek Ervaren Gezondheid’)
[52], a Dutch 13-item questionnaire used to
measure the health of a population, often used in
social science research. The items consist of
somatic symptoms like headache, nervousness and
lethargy and respondents indicate whether they
have these symptoms or not. A higher score
indicates more somatic symptoms and a worse
perceived health.
c. Fatigue is measured by the Checklist Individual
Strength (CIS) [53], which quantifies subjective
fatigue and related behavioral aspects. The CIS
consists of 20 statements for which the respondent
has to indicate on a 7-point scale to what extent
the particular statement applies to him or her
(1 = Yes, that is true; to 7 = No, that is not true).
The statements refer to four fatigue aspects:
(1) subjective fatigue (2) reduced motivation
(3) reduced activity and (4) reduced concentration.
For the CIS a cut-off point of >76 has been
established [54]. People with a score above this
cut-off point are at an increased risk of long-term
sickness absence.
d. Self-esteem is measured by the Rosenberg Self-
Esteem Scale (RSE) [55]. The RSE is a 10-item
questionnaire that measures global self-esteem.
Items are scored on a 4-point scale. A higher score
indicates a more positive self esteem. Scores below
21 indicate low self-esteem.
e. Eating disorders are measured by the Eating
Disorder Examination-Questionnaire (EDE-Q)
[56], a 36 item questionnaire that measures
concerns about shape, weight and eating, restraint
and binge eating. Subscale scores for restraint and
shape, weight and eating concern range between
0–6. A higher score indicates more severe eating
psychopathology. Because binge eating cannot be
measured reliably by the EDE-Q, we use a
questionnaire composed by Werrij, et al. [28] for
diagnosing binge eating disorder (BED), based on
the DSM-IV criteria for BED. BED is diagnosed
when respondents report eating binges twice a
week or more.
f. Session rating. How the participants value the
sessions is measured by the Session Rating Scale
(SRS) [57]. The SRS is an ultra brief alliance
measure designed specifically for every session
clinical use. The SRS consists of four 10-cm visual
analogue scales (relationship scale, goals and topic
scale, approach or method scale, overall evaluation
scale), with instructions to place a hash mark on a
line (continuum) with negative responses depicted
on the left and positive responses indicated on the
Table 4 baseline characteristics pilot group
Baseline (n=13)
Sex (%) Males 25%
Females 75%
Age (y) 49.5
Insulin dependant (%) Insulin dependant 75%
Non-insulin dependant (OAD) 25%
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score lower than 36 overall, or 9 on any scale,
could be a source of concern and therefore
prudent to invite the client to comment.
5. Lifestyle
a. We developed a lifestyle questionnaire on diet
history, smoking, drinking habits, drug use and
hours sleep. (Additional file 1)
b. Physical activity is measured using the SQUASH
(Short Questionnaire to Assess Health Enhancing
Physical Activity) [58]. The SQUASH collects days
per week, average time per day, and effort for
physical activities such as commuting activities,
leisure time and sport activities, household
activities, and activities at work or school. Total
minutes of activity are calculated for each question
by multiplying frequency (days per week) by
duration (minutes per day). Activity scores for
separate questions are calculated by multiplying
total minutes of activity by an intensity score
(range 1–9). The total activity score is calculated
by taking the sum of the activity scores for the
separate questions.
6. Cost-effectiveness
a. Quality of life is measured by the EuroQol
(EQ-5D) [59,60]. The EQ-5D is 5-item self report
questionnaire on which participants report if they
experience any problems in mobility, self-care,
usual activities, pain and anxiety/depression. Each
dimension has 3 levels: no problems, some
problems and severe problems. The scores on the
three dimensions can be combined into one co
called ‘utility’ score, which represents the societal
value of quality of life. The utility score has a range
from 1.00 (the value of health without health
problems) till 0.00 (the value of health problems as
bad a death). This societal value of quality of life is
used as input for so called Quality Adjusted Life
Years (QALY) analysis, as the societal perspective
is the preferred perspective in health economics.
The EuroQol instrument contains also the
EQ-VAS, a vertical visual analogue scale with the
anchors best imaginable health (score of 100)
and worst imaginable health (score of 0). This
EQ-VAS represents the patient’s perspective of
quality of life.
b. Costs are measured by the Trimbos/iMTA
Questionnaire for Costs associated with Psychiatric
Illness (TiC-P) [61]. The TiC-P measures direct
medical costs due to healthcare utilization duringthe past four weeks. Also, it registers the indirect
non-medical costs due to productivity loss during
the past two weeks.Patient follow-up and compliance
Follow-up measurements will take place combined with
evaluation group meetings.
For patients in both groups, follow-up visits to the
physician, diabetes nurse and dietician are registered.
A common limitation of weight loss studies is a select-
ive loss to follow-up: higher drop-out rates occur among
patients, who do not achieve their weight loss goals. We
want to tackle this problem by use of incentives to keep
all patients in the trial: motivating phone calls of the re-
searcher, little gifts during the program, etc.
Further more, we will perform a follow-up and analysis
of the drop-outs after completion of the study and com-
pare completers and drop-outs at base-line. For this pur-
pose, the drop-outs will be interviewed by a medical
student, who is not involved in the study.
Compliance to the intervention is assessed by registra-
tion of the attendance to the CPI sessions: participants are
considered non-compliant when they are absent on more
then 8 sessions. Since we expect that the treatment will be
less effective when more then 8 sessions are missed, this
non-compliant participants will be considered drop-outs.
We have conducted a pilot study to improve our re-
search protocol. We will not perform interim analyses
and we will not define stopping rules, since the interven-
tion has no serious side-effects.
Data/results pilot study
In order to test the protocol we conducted a pilot study,
in which we included 13 patients to asses the study de-
sign and logistic pathways of the VLCD-period and the
first 10 weeks of CPI. In this pilot study, we found that
the protocol was feasible and that no major changes had
to be done. The only change we made was in the lay-out
of the questionnaires, making them better understand-
able to our participants. Results of this pilot study (base-
line and T=4 months) are shown below (Table 4 and 5).
Statistical analyses
All analyses will be conducted according to the
intention-to-treat as well as the on-treatment principle.
Table 5 Outcome measurements pilot group
Baseline (n=13) T1 = 4 months (n=13) 95%CI
Weight (kg) 114.8 106.0*** [5.2-12.4]
Waist circumference (cm) 121.4 113.7** [3.2-12.2]
Systolic BP (mmHg) 144.6 127.9* [1.1-32.2]
Diastolic BP (mmHg) 86.1 78.0 [−0.4-16.7]
Total cholesterol (mmol/l) 5.0 4.5 [−0.2-1.3]
HDL cholesterol (mmol/l) 1.7 1.3 [−0.3-1.3]
LDL cholesterol (mmol/l) 2.6 2.5 [−0.3-0.5]
Triglycerides (mmol/l) 3.6 2.6 [−1.1-3.0]
HbA1c (mmol/mol) 66.3 66.6 [−9.8-9.1]
Insulin (IU) 82.3 32.3* [7.3-94.7]
Depression score (HAD) 5.7 4.6 [−1.5-3.7]
>8 = (sub)clinical
Paired samples T-test *p<0.05 **p<0.01 ***p<0.001.
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less then 8 sessions CPI.
At baseline, comparability between the control- and
intervention group will be assessed to test the success of
the randomization. As measures of central tendency for
numerical data we will use the mean (in case of normal
distribution) and median values (in case of non-normal
distribution), with respectively the standard deviation
and interquartile range as measures of dispersion.
Mixed modelling, also known as random effect model-
ling, multilevel or hierarchical linear regression analyses
will be applied for longitudinal analyses of the data.
Mixed modelling can efficiently handle data with missing
and unbalanced time-points. It corrects for bias when
absence of data is dependent on characteristics that are
present in the models (missing at random, MAR) [62].
There will be two levels in the models. The patients con-
stitute the upper level, their repeated measures the lower
level. First, for each outcome variable a saturated model
will be postulated, with the primary or secondary out-
comes as dependent variables. The saturated models will
include treatment group, time, quadratic time, logarithm
of time and all treatment-time interactions as fixed
effects. The deviance statistic [63] using restricted max-
imum likelihood [64] will be applied to determine the
covariance structure. Next, using Wald tests, the satu-
rated models will be reduced by eliminating insignificant
fixed effects. The significance of the difference between
the saturated models and the parsimonious final models
will be determined with the deviance statistics using or-
dinary likelihood.
Discussion
To our knowledge, this trial is the first randomized con-
trolled trial to test the effects of an integrated multi-
model cognitive group therapy in the battle againstweight regain after a successful weight loss intervention
(VLCD) in patients with type 2 diabetes. Weight regain
is common in the obese population in general, but even
more pronounced in the diabetes type 2 population, and
with more devastating effects on their health outcomes.
The strength of this study is the combined psychological
intervention (CPI) of cognitive restructuring, problem
solving treatment and proactive coping, which will pro-
vide powerful tools to the participants for maintaining
behavioral change and improving health outcomes. We
expect that adding CPI to a VLCD will be effective in
maintaining weight loss, improving lifestyle and, as a re-
sult, leading to improved glycaemic control and a reduc-
tion of cardiovascular risk.
We expect that a number of factors may influence the
treatment effect, therefore we will also examine potential
determinants of weight maintenance, such as depression,
anxiety, self-esteem, fatigue, somatic symptoms, eating
disorders and lifestyle. Apart from being predictive for
the success of the intervention, these factors may be
changed by the treatment itself and therefore will be fol-
lowed over time as secondary outcome measurements.
It is expected that if the intervention is successful, it
will also be cost effective since the costs of group coun-
selling are relatively low and the expected reduction of
medication, prevention or delay of complications and a
reduction of hospital admissions are considered major
cost savings. If the therapy is indeed effective, a formal
cost effectiveness analysis will be performed.
Few studies have implemented interventions to sustain
weight loss for longer then 18 months. In this study, we
opt for a follow-up period of 2 years, enabling predic-
tions on long-term behavioral change and weight main-
tenance. During the follow-up period, participants will
have relapse-prevention group meetings with increasing
intervals to stabilize behaviour. It is known that the
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the therapist stops, and one can therefore expect that
the participants experience a relapse in their behaviour
after the follow-up period. The last session op CPI will
be at 1,5 years after randomization, leaving the partici-
pants 6 months ‘to themselves’. Obviously, our patients
remain under supervision of the healthcare team after
completion of the study and will be encouraged to con-
tinue their good habits. Nevertheless, after 5 years, we
will try to repeat the assessment of the main outcome
variables to determine the long-term effect.
Limitations
This trial is explanatory in design in relation to the mea-
sures of process but pragmatic in terms of the compari-
son with usual care rather than a specified alternative
group. We chose this design to enable analysis of an
additional intervention on top of usual care in a popula-
tion already receiving multiple interventions. The prag-
matic approach and planned economic analysis aim to
facilitate implementation of the intervention when suc-
cessful, but this design does not identify the optimal psy-
chological therapy.
If the intervention is successful, it cannot be ascer-
tained which of the 3 therapies involved determined the
success. However, each of the treatments has been stud-
ied separately and is more or less proven effective in
achieving weight reduction and maintenance [20,26,28-
32,34-36,40]. We expect that a diet with a combination
of several forms of cognitive behaviour therapy together
will have a greater impact than the individual factors.
Clearly the assumption is that the overlap of effects of
the different types of interventions is negligible. This is
not necessarily true. Hence, the present study is designed
to study the effect of a combination therapy, but cannot
identify the optimal combination of interventions.
Another limitation is the comparison to usual care
only. One could argue that the participants in the inter-
vention group may benefit from the attention they get,
and not necessarily from the CPI. In our study design, it
is impossible to distinguish between the effect of atten-
tion and the effect of the intervention itself. Our choice
to compare our intervention on top of usual care with
usual care only, is based on the fact that this kind of
comparative effectiveness design has more clinical rele-
vance. Such design is a necessary condition for a cost
effectiveness analysis, as cost effectiveness is measured in
relation to the dominant alternative treatment strategy.
Moreover, the individual interventions have been shown
effective in comparison with other psychological inter-
ventions, exercise or placebo as a control [27,35,40,65].
We are aware of the fact that our population is not
generalizable to the entire group of overweight patients
with type 2 diabetes.One can speculate that patients, who agree to partici-
pate in the study and are able to achieve a 5% weight re-
duction in 8 weeks, are expected to be more motivated
then patients, who refuse to participate or who fail to
lose sufficient weight. Randomization will distribute this
selection bias equally to the CPI and the control group.
Nonetheless, our findings will solely be applicable to
patients, who are motivated to reduce their body weight.
Our hospital is a tertiary referral centre and as a result
the patients often have end stage disease with multiple
complications. Due to this selection, motivation, compli-
ance and treatment outcome are expected to be low, po-
tentially resulting in underestimation of the effect.
However, GP’s will also be able to refer their eligible
patients directly to the trial. Those patients often have
less severe disease and complications.
Insufficient command of the Dutch language is an ex-
clusion criterion of this investigation, because the cogni-
tive training is given in Dutch and the workbook and
homework assignments must be understood and carried
out in Dutch as well. In this way, a part of the immigrant
population is excluded and the study population will not
reflect the entire diabetic population of the Erasmus MC.
We will use incentives (motivating phone calls, little
booklets etc.) to minimize drop-out. This effect will be
the same for the control group and the intervention
group, not affecting the results. However, it will have an
effect on the generalizability of the study because the
less motivated participants are more likely to remain in
the study where they would normally drop-out.
We are aware of the impact, especially on the control
group, of the large measurement burden due to all the
psychological questionnaires. We will discuss this with the
participants beforehand and expect that they find 5 times
30 minutes of completing questionnaires is acceptable in
the light of the weight loss intervention they will receive.
Future implementation
If this intervention proves to be effective and cost-effective,
we will promote implementation into diabetes care.
In the present study, we use a VLCD because it leads
to quick and substantial weight loss, but off course the
multi-model cognitive therapy can be combined with
any weight loss intervention (i.e. low calorie diet, low
carbohydrate diet, exercise), to sustain the effect.
The study will start in 2010 and the inclusion of
patients will take approximately 3 years. After the
follow-up period of 2 years, we expect the results to be-
come available in 2015.Additional file
Additional file 1: Lifestyle questionnaire.
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